1-[5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl]methanamine | 944897-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl]methanamine
• 英文别名: [5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]methanamine
• CAS: 944897-72-7
• 化学式: C₉H₈ClN₃O
• 分子量: 209.635
• InChiKey: YWHKJARWLAQSLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzoic acid 、 1-[5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl]methanamine 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 N-{[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzamide
  参考文献：
  名称：

  Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators

  摘要：

  We report the discovery and optimization of a novel series of dihydrobenzofuran amides as gamma-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain A beta 42 lowering activity at 100 mg/kg po dose. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.059

文献信息

• PYRAZOLE COMPOUNDS AND USE THEREOF
  申请人：Takagi Masaki

  公开号：US20090036450A1

  公开（公告）日：2009-02-05

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

  本发明的吡唑化合物由以下一般式（I）表示。本发明的吡唑化合物或其盐或溶剂化物强力抑制肝糖原磷酸化酶，因此，可用作糖尿病的治疗或预防剂。其中，每个符号如规范中所述。
• 含5-芳基-1,3,4-噁二唑结构的吡唑酰胺类化 合物的制备方法和应用
  申请人：南通大学

  公开号：CN106866649B

  公开（公告）日：2019-06-25

  本发明涉及一种含5‑芳基‑1,3,4‑噁二唑结构的吡唑酰胺类化合物(I)及其制备方法和应用。以取代基吡唑甲酰基氯(II)与5‑芳基‑1,3,4‑噁二唑‑2‑甲基胺(III)缩合得到。所述含5‑芳基‑1,3,4‑噁二唑结构的吡唑酰胺类化合物对有害昆虫具有效的防治效果，该化合物可用于制备农业、园艺等领域的杀虫剂。。
• PYRAZOLES AND USE THEREOF AS DRUGS
  申请人：Japan Tobacco Inc.

  公开号：EP2096111A1

  公开（公告）日：2009-09-02

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specification.

  本发明的吡唑化合物由以下通式（I）表示。本发明的吡唑化合物或其盐或其溶液能有效抑制肝糖原磷酸化酶，因此可用作糖尿病的治疗或预防药物。 其中各符号表示如说明书所述。
• Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators
  作者：Martin Pettersson、Douglas S. Johnson、Chakrapani Subramanyam、Kelly R. Bales、Christopher W. am Ende、Benjamin A. Fish、Michael E. Green、Gregory W. Kauffman、Ricardo Lira、Patrick B. Mullins、Thayalan Navaratnam、Subas M. Sakya、Cory M. Stiff、Tuan P. Tran、Beth C. Vetelino、Longfei Xie、Liming Zhang、Leslie R. Pustilnik、Kathleen M. Wood、Christopher J. O’Donnell

  DOI：10.1016/j.bmcl.2012.02.059

  日期：2012.4

  We report the discovery and optimization of a novel series of dihydrobenzofuran amides as gamma-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain A beta 42 lowering activity at 100 mg/kg po dose. (C) 2012 Elsevier Ltd. All rights reserved.